Zobrazeno 1 - 10
of 59
pro vyhledávání: '"VSV-EBOV"'
Autor:
Ha-Na Lee, Biying Xu, Aaron P. Lewkowicz, Kaliroi Engel, Logan Kelley-Baker, Ian L. McWilliams, Derek D.C. Ireland, Jennifer L. Kielczewski, Jinbo Li, Robert N. Fariss, Mercedes M. Campos, Alina Baum, Christos Kyratsous, Kristen Pascal, Chi-Chao Chan, Rachel R. Caspi, Mohanraj Manangeeswaran, Daniela Verthelyi
Publikováno v:
EBioMedicine, Vol 104, Iss , Pp 105170- (2024)
Summary: Background: Ebola virus disease (EVD) survivors experience ocular sequelae including retinal lesions, cataracts, and vision loss. While monoclonal antibodies targeting the Ebola virus glycoprotein (EBOV-GP) have shown promise in improving pr
Externí odkaz:
https://doaj.org/article/22fa242296984e11a7988fdc6dae6cdd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ha-Na Lee, Ian L. McWilliams, Aaron P. Lewkowicz, Kaliroi Engel, Derek D. C. Ireland, Logan Kelley-Baker, Seth Thacker, Pedro Piccardo, Mohanraj Manangeeswaran, Daniela Verthelyi
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 2076-2089 (2021)
Ebola virus (EBOV) infections cause haemorrhagic fever, multi-organ failure and death, and survivors can experience neurological sequelae. Licensing of monoclonal antibodies targeting EBOV glycoprotein (EBOV-GP) improved its prognosis, however, this
Externí odkaz:
https://doaj.org/article/d872a120c2254056bd329b2d88e1c4f7
Autor:
Kyle L. O’Donnell, Chad S. Clancy, Amanda J. Griffin, Kyle Shifflett, Tylisha Gourdine, Tina Thomas, Carrie M. Long, Wakako Furuyama, Andrea Marzi
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
The ongoing COVID-19 pandemic has resulted in global effects on human health, economic stability, and social norms. The emergence of viral variants raises concerns about the efficacy of existing vaccines and highlights the continued need for the deve
Externí odkaz:
https://doaj.org/article/4723af40df4f4d9e985889272c0e5386
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 10, Pp 2269-2285 (2019)
The devastating Ebola virus (EBOV) outbreak in West Africa in 2013–2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogen
Externí odkaz:
https://doaj.org/article/19ae94ab491e464ca6afc785029703c8
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 9, Pp 2107-2113 (2018)
The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the
Externí odkaz:
https://doaj.org/article/cf72277532f54d55a4d5793ca52909fa
Autor:
Guodong Liu, Wenguang Cao, Abdjeleel Salawudeen, Wenjun Zhu, Karla Emeterio, David Safronetz, Logan Banadyga
Publikováno v:
Pathogens, Vol 10, Iss 9, p 1092 (2021)
Vesicular stomatitis virus (VSV), which belongs to the Vesiculovirus genus of the family Rhabdoviridae, is a well studied livestock pathogen and prototypic non-segmented, negative-sense RNA virus. Although VSV is responsible for causing economically
Externí odkaz:
https://doaj.org/article/c5e2fc755c224c75b8356b3bc5310777
Publikováno v:
mBio, Vol 10, Iss 3 (2019)
ABSTRACT Ebola virus (EBOV) is a single-stranded RNA virus that causes Ebola virus disease (EVD), characterized by excessive inflammation, lymphocyte apoptosis, hemorrhage, and coagulation defects leading to multiorgan failure and shock. Recombinant
Externí odkaz:
https://doaj.org/article/22b8b5e8b08d41a8839aae168a0e384a
Autor:
Sarah-Kim Friedrich, Rosa Schmitz, Michael Bergerhausen, Judith Lang, Lamin B. Cham, Vikas Duhan, Dieter Häussinger, Cornelia Hardt, Marylyn Addo, Marco Prinz, Kenichi Asano, Philipp Alexander Lang, Karl Sebastian Lang
Publikováno v:
Vaccines, Vol 8, Iss 1, p 142 (2020)
Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after s
Externí odkaz:
https://doaj.org/article/6f5a994595b74c0a86234ef732515879
Autor:
Logan Banadyga, Andrea Marzi
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 5, Pp 401-402 (2017)
Externí odkaz:
https://doaj.org/article/78eb45113ed94d0b94bfe6bd1d7ee211